[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-atrophy-or-weakness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-atrophy-or-weakness":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,53,77,110,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100639066","phase-2-tcm-formula-vs-hmb-in-pre-frail-elders-muscle-strength-and-bone-status-100639066",false,"NCT07597850","TCM Formula vs. HMB in Pre-Frail Elders: Muscle Strength and Bone Status","Effects of Traditional Chinese Medicine (TCM) Formula vs. HMB on Muscle Strength and Bone Status in Pre-Frail Elders: A Comparative Study","TCM-HMB-PF","Inclusion Criteria:\n\n* Male or female participants aged 65 years or older at the time of screening.\n* Body Mass Index less than 30 kilograms per square meter.\n* Identified as pre-frail according to the Fried frailty phenotype, meeting 1 to 2 of the following 5 criteria: 1) Hand grip strength below specific thresholds based on gender and Body Mass Index. For males, Body Mass Index 24 or less is 29 kilograms or less, Body Mass Index 24.1 to 28 is 30 kilograms or less, Body Mass Index greater than 28 is 32 kilograms or less. For females, Body Mass Index 23 or less is 17 kilograms or less, Body Mass Index 23.1 to 26 is 17.3 kilograms or less, Body Mass Index 26.1 to 29 is 18 kilograms or less, Body Mass Index greater than 29 is 21 kilograms or less. 2) Slow walking speed. For a 4-meter distance, walking time of 7 seconds or more for males 173 centimeters or shorter, or 6 seconds or more for males taller than 173 centimeters. For females 159 centimeters or shorter, 7 seconds or more, or 6 seconds or more for females taller than 159 centimeters. 3) Self-reported exhaustion. Answering 3 days or more per week to either feeling that everything was an effort or could not get going in the past week. 4) Unintentional weight loss. Loss of 3 kilograms or more or more than 5 percent of body weight in the past year. 5) Low physical activity. Weekly energy expenditure less than 383 kilocalories for males or less than 270 kilocalories for females.\n* Ability to safely complete a 6-meter walk test in a single attempt without assistance or using only simple aids such as a cane.\n* Clinically stable condition allowing for follow-up visits every 4 weeks and participation in all study-related assessments.\n* Willingness to provide existing test data from within 90 days prior to randomization, including Bone Mineral Density by DXA and serum biochemistry or urinalysis results.\n* Sufficient cognitive function to understand the study and sign the informed consent form, or with the assistance of a legal representative.\n* Willingness to maintain existing diet and exercise habits during the study and not start high-intensity exercise programs or large amounts of nutritional supplements.\n\nExclusion Criteria:\n\n* Major acute illness such as acute myocardial infarction, pneumonia, or acute stroke within 2 weeks prior to screening.\n* Major organ dysfunction, including renal function with estimated glomerular filtration rate less than 45 milliliters per minute per 1.73 square meters within 1 month prior to screening, liver function with AST or ALT greater than 3 times the upper limit of normal within 1 month prior to screening, NYHA Class III or IV heart failure, or severe COPD requiring long-term oxygen therapy.\n* Unplanned hospitalization within 1 month prior to screening, or major surgery with incomplete functional recovery within 3 months prior to screening.\n* Current malignant tumor under treatment, or less than 12 months since the completion of cancer treatment.\n* Use of supplements containing the same ingredients as the study interventions, or products that may affect the primary endpoint including HMB, creatine, branched-chain amino acids, or high-dose protein powder within 4 weeks prior to screening.\n* Known significant clinical allergy or hypersensitivity to any components of the study formula or HMB nutritional supplement.\n* Moderate to severe dementia, severe depression, or other psychiatric disorders resulting in inability to cooperate without a legal representative.\n* Participation in other interventional clinical trials involving drugs, biologics, or nutritional supplements within 3 months prior to screening.\n* New initiation or dose adjustment of medications affecting muscle or bone metabolism within 3 months prior to screening, including systemic glucocorticoids, anabolic steroids, testosterone, or growth hormones.\n* Any other condition that, in the opinion of the investigator, makes the participant unsuitable for the study due to safety or compliance concerns.","ALL","65 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to compare the effects of a standardized Traditional Chinese Medicine (TCM) formula versus beta-hydroxy-beta-methylbutyrate (HMB) on muscle strength and bone health in pre-frail older adults . Pre-frailty is a critical stage where functional decline may still be reversed through proper intervention. The study will enroll 90 participants aged 65 years or older who meet the criteria for pre-frailty. Participants will be randomly assigned to either the TCM group (receiving a standardized herbal powder formula) or the HMB group (receiving nutritional supplement tablets) for 24 weeks . The primary objective is to evaluate the change in handgrip strength from baseline to Week 12 . Researchers will also assess changes in skeletal muscle mass, bone mineral density, and overall physical performance . The goal is to determine if the TCM formula is an effective alternative or complementary intervention for managing geriatric frailty.",[27,28,29,30,31],"Pre-Frailty","Sarcopenia","Muscle Atrophy or Weakness","Osteoporosis","Aging",[33,34,35,36,37,38,39],"Traditional Chinese Medicine","HMB (Hydroxy-beta-methylbutyrate)","Muscle Strength","Handgrip Strength","Body Composition","Elderly Health","Randomized Controlled Trial","RECRUITING","2026-05-13",{"date":43,"type":44},"2026-05-19","ACTUAL",{"date":46,"type":44},"2026-04-02",{"date":48,"type":21},"2026-12-31",{"name":50,"class":51},"Tri-Service General Hospital","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":52},"100530315","early-phase-1-metformin-and-muscle-recovery-100530315","NCT06185179","Metformin and Muscle Recovery","Use of Metformin to Improve Muscle Regrowth in Older Adults","Inclusion Criteria:\n\n1. Age between 60y and older\n2. BMI: \\\u003C30 kg\u002Fm2\n3. Good general medical health, ambulatory and in independent living setting\n4. Adequate upper body strength to use assistive walking device (crutches, walker, etc) as assessed by PI\u002Fstaff during screening\n5. Clinical Frailty Scale score \\\u003C 3\n6. Mini-Cog score \\> 3\n\nExclusion Criteria:\n\n1. History of cardiovascular disease (e.g., CHF, CAD, MI, CVA)\n2. History of endocrine or metabolic disease such as hypo\u002Fhyperthyroidism and diabetes (Treated hypo\u002Fhyperthyroid for at least 6 months will be permitted)\n3. History of kidney disease or failure (CKD \\> stage 4; serum creatinine \\>1.5mg\u002FdL)\n4. History of vascular disease\n5. Risk of DVT including family history of thrombophilia, DVT, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb\\>18 g\u002FdL) or thrombocytosis (platelets\\>400x103\u002FmL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocystinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombine III\n6. Use of anticoagulant therapy (e.g., Coumadin, heparin)\n7. Uncontrolled hypertension - Elevated systolic pressure \\>150 or a diastolic blood pressure \\> 100\n8. Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators)\n9. Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma\n10. Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular\u002Ftopical\u002Finhaled therapeutic or physiologic doses of corticosteroids will be permitted)\n11. Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement will be permitted)\n12. Inability to abstain from smoking or vaping for duration of study\n13. Currently taking estrogen products (topical estrogen products will be permitted)\n14. Currently on weight loss diet or medication\n15. History of stroke with motor disability\n16. A recent history (\\\u003C12 months) of GI bleed\n17. History of liver disease or AST\u002FALT 2 times above the normal limit\n18. History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)\n19. Any staff members who report directly to the principal investigators",true,"60 Years",{"count":63,"type":21},50,[65],"EARLY_PHASE1","A hallmark of aging is an impaired ability to adequately recover following a stressor, such as muscle disuse, resulting in muscle fibrosis and weakness thereby increasing the risk for falls and loss of independence. Mechanistic-based therapeutic strategies to enhance muscle recovery in older adults do not exist. Metformin has been implicated to have positive effects on muscle size and function through non-glycemic mechanisms. Metformin has been shown to enhance macrophage function and lessen cellular senescence burden by targeting SASP in a variety of muscle interstitial cells. However, the role of metformin to improve muscle recovery in older adults following disuse atrophy through immunomodulating and senomorphic mechanisms have not been examined. Therefore, the purpose of this study is to conduct a randomized, double blind, placebo-controlled clinical trial in older adult participants to determine if short-term metformin delivery (vs placebo) during the recovery phase following disuse atrophy can improve muscle regrowth.",[29],"2025-12-01",{"date":70,"type":44},"2025-12-05",{"date":72,"type":44},"2024-09-01",{"date":74,"type":21},"2030-05-31",{"name":76,"class":51},"University of Utah",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":52},"100602782","neuromuscular-electrical-stimulation-in-critically-ill-patients-aged-80-and-over-100602782","NCT07127991","Neuromuscular Electrical Stimulation in Critically Ill Patients Aged 80 and Over","Impact of Neuromuscular Electrical Stimulation on Muscle Mass, Strength, and Functionality in Critically Ill Oldest Old Patients: a Randomized Controlled Trial","NMES-ICU80","Inclusion Criteria:\n\n* People aged 80 years or older.\n* Hospitalized in the Adult Critical Care Unit of Dr. Hernán Henríquez Aravena Hospital in Temuco.\n* Estimated mechanical ventilation time greater than 72 hours.\n\nExclusion Criteria:\n\n* Patients with prior neurological complications.\n* Patients with severe dependence prior to admission.\n* Patients with difficult-to-manage hemodynamic instability.\n* Patients with accessory elements that limit assessment.\n* Patients with lower limb amputation.\n* Patients in the prone position.\n* Patients with loss of skin integrity.\n* Patients expected to remain in the unit for less than 72 hours.\n\nPatients transferred from other services with a stay of more than 72 hours.","80 Years",{"count":87,"type":21},30,[89],"NA","The aim of this clinical trial is to evaluate the effectiveness of Medium-Frequency Neuromuscular Electrical Stimulation, in combination with standard physical therapy, compared to standard physical therapy alone, on muscle mass, muscle strength, and functionality in critically ill patients aged 80 and over during their hospital stay. The safety of the intervention and the standardization of protocol parameters will also be assessed.\n\nThe main research questions are:\n\n* Does the implementation of a standardized Medium-Frequency Neuromuscular Electrical Stimulation protocol, in combination with standard physical therapy, compared to standard physical therapy alone, help attenuate the loss of skeletal muscle mass, strength, and functionality in critically ill patients aged 80 and over?\n* Is the use of this protocol and its proposed parameters safe for critically ill patients aged 80 and over? The study will consist of applying a standardized Medium-Frequency Neuromuscular Electrical Stimulation protocol to oldest old patients admitted to the Intensive Care Unit of Dr. Hernán Henríquez Aravena Hospital in Temuco, Chile. The sample will consist of oldest old participants (≥80 years), who will be randomly divided into two subgroups: a control group that will receive standard physical therapy typically provided during hospitalization, and an experimental group that will receive the same standard therapy plus Medium-Frequency Neuromuscular Electrical Stimulation, which will begin within the first 48 hours of Intensive Care Unit admission.\n\nThe following variables will be assessed in both groups (control and experimental), from Intensive Care Unit admission to hospital discharge:\n\n* Skeletal muscle mass characteristics and evolution (quadriceps femoris and anterior tibialis muscle thickness), measured by ultrasonography.\n* Handgrip strength, measured using a digital hand dynamometer.\n* Inspiratory muscle strength, assessed using a pimometer.\n* Peripheral muscle strength, evaluated with the Medical Research Council Sum Score (MRC-SS).\n* Functionality, assessed by the Functional Status Score for the Intensive Care Unit (FSS-ICU) .\n* Independence in basic activities of daily living, measured using the Barthel Index.\n* Quality of life, evaluated using the Short Form-36 Health Survey (SF-36).\n* Cognitive impairment, assessed through the Montreal Cognitive Assessment (MoCA).\n* Frailty, measured using the Clinical Frailty Scale (CFS).",[92,29,93],"Intensive Care Units (ICUs)","Old and Very Old People",[95,96,97,98,99],"MUSCLE ATROPHY","FUNCTIONAL STATUS","ICU","OLDER ADULTS","NMES","NOT_YET_RECRUITING","2025-08-13",{"date":103,"type":44},"2025-08-17",{"date":105,"type":21},"2025-09",{"date":107,"type":21},"2026-12",{"name":109,"class":51},"Universidad de La Frontera",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":60,"sex":17,"minAge":117,"maxAge":85,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":52},"100510421","c-protein-in-fatigue-and-aging-100510421","NCT05926219","C-Protein in Fatigue and Aging","Skeletal Muscle Myosin Binding Protein C in Fatigue and Aging","Inclusion Criteria:\n\n* Adults between the ages 18-35 or 65-80 years\n* Healthy by self-report\n* Willing to participate in all aspects of the study design including muscle biopsy, unilateral exercise, and physical activity monitoring\n* Fluent in English (due to lack of translation services, it is not practical to conduct the study using a language other than English).\n\nExclusion Criteria:\n\n* Orthopaedic limitation (severe knee osteoarthritis, prior joint replacement, etc.).\n* Volunteer has dementia or related mental issues that potentially put the subject at risk as determined by prior diagnosis.\n* Volunteer has known untreated endocrine disease (hypo\u002Fhyper thyroidism, Addison's Disease or Cushing's syndrome, etc.)\n* Volunteer has untreated\u002Fpoorly-controlled hypertension (stage 2, per American College of Cardiology \\[\\>140\u002F90 mmHg\\]).\n* Volunteer has significant heart, liver, kidney or respiratory disease.\n* Volunteer has diabetes (insulin dependent or non-insulin dependent).\n* Volunteer has known coagulopathies.\n* Volunteer has taken anabolic steroids in the prior six months.\n* Volunteer has received treatment for cancer (other than effective Mohs Surgery for successful removal of basal cell or squamous cell carcinomas)\n* Unexpected weight loss \\>5kg is last 12 months\n* Volunteer is an active smoker or quit within the last year.\n* Volunteer has known current alcohol or drug use disorder (AUD; defined as binge drinking of \\>4 days in the last month. Binge drinking is \\>5 drinks for men and \\>4 drinks for women, per occasion). Or, if a volunteer reports drinking in excess of \"low risk\" per NIAAA (\\>7 drinks\u002Fweek for men and \\>3 drinks\u002Fday for women and \\>14 drinks\u002Fweek and \\>4 drinks\u002Fday).\n* Volunteer has a diagnosed neuromuscular disorder.\n* Volunteer has allergy to lidocaine.","18 Years",{"count":119,"type":21},24,[89],"This study is investigating changes to the proteins in skeletal muscle that contribute to reduced muscle size and muscle function that occurs with aging.",[31,29,123,28],"Sarcopenia in Elderly",[125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142],"muscle","aging","elderly","myosin","protein","sarcomere","exercise","function","atrophy","contractile","strength","balance","mobility","MyBP-C","fiber","biopsy","skeletal muscle","fatigue","2025-05-06",{"date":145,"type":44},"2025-05-07",{"date":147,"type":44},"2017-11-06",{"date":149,"type":21},"2027-01",{"name":151,"class":51},"University of Oregon",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":60,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":170,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":52},"100501881","yoomi-effect-of-gamified-physical-therapy-exercise-software-on-inpatient-mobility-100501881","NCT05815017","YOOMI: Effect of Gamified Physical Therapy Exercise Software on Inpatient Mobility","YOOMI","Inclusion Criteria:\n\n* \\>= 65 years of age\n* English-fluency in reading and speaking\n* Capacity to consent\n* Enrolled in HELP program\n* Attending physician confirms there are no medical contraindications to in-bed exercises\n\nExclusion Criteria:\n\n* Unstable Psychiatric Illness\n* Unstable\u002FCritically Ill Patients requiring ICU-level of care\n* Surgical tube present (e.g. JP drains)\n* Surgery during the hospitalization\n* Bed Rest Activity Order",{"count":160,"type":21},80,[89],"Patients admitted to the hospital often develop functional impairments due to being in bed most of the day. Each day of bedrest leads to significant muscle loss. As a result, many patients become dependent on others or require rehabilitation at a facility to improve mobility and function prior to returning home. Staff in the hospital is limited and often unable to mobilize patients every day while hospitalized. The investigators are testing a new experimental gamified physical therapy exercise software to see if it can be a fun, enjoyable way to help mobilize patients without the assistance of staff. The primary aim of this pilot\u002Fproof of concept study is to determine whether gamified physical therapy software can help inpatients exercise within the safety of their own beds and preserve pre-hospitalization function.",[164,165,29,166,167,168,169],"Weakness, Muscle","Delirium in Old Age","Muscle Loss","Hospital Acquired Condition","Physical Disability","Physical Inactivity",[171,172,173,174,175,176],"Artificial Intelligence (AI)","Physical Therapy","Hospitalization related muscle atrophy","Hospitalization associated decline","Inpatient rehabilitation","AI driven physical therapy","2024-03-06",{"date":179,"type":44},"2024-03-08",{"date":181,"type":44},"2023-11-29",{"date":183,"type":21},"2024-12",{"name":185,"class":51},"Rutgers, The State University of New Jersey"]